Company Filing History:
Years Active: 2017-2020
Title: Oleg E Akilov: Innovator in Cancer Immunotherapy
Introduction
Oleg E Akilov is a prominent inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative research and patented inventions. With a total of 2 patents, Akilov's work focuses on enhancing the effectiveness of interferon therapy for cancer patients.
Latest Patents
Akilov's latest patents include groundbreaking methods for predicting patient responses to interferon therapy. The first patent, titled "Reactive oxygen species production by myeloid-derived suppressor cells as a predictor of patient response to interferon-α therapy," outlines methods and materials for more effectively treating patients with interferon. This invention is based on the discovery that the clinical response to interferon therapy is partially mediated by the inhibition of myeloid-derived suppressor cell (MDSC) activation. A significant decrease in reactive oxygen species (ROS) production by MDSC after interferon therapy serves as a predictive measure of overall response to immunotherapy in cancer patients.
The second patent, "Activation of myeloid-derived suppressor cells as a predictor of patient response to interferon-α therapy," further explores similar concepts. It emphasizes the importance of MDSC activation in predicting patient responses to interferon therapy, reinforcing the findings of his first patent.
Career Highlights
Oleg E Akilov is affiliated with the University of Pittsburgh, where he conducts his research and develops his innovative ideas. His work has garnered attention in the medical community, particularly for its potential to improve treatment outcomes for cancer patients undergoing interferon therapy.
Collaborations
One of Akilov's notable collaborators is Larisa J Geskin. Together, they have worked on advancing the understanding of immunotherapy and its applications in cancer treatment.
Conclusion
Oleg E Akilov's contributions to cancer immunotherapy through his patented inventions highlight his role as an innovator in the field. His research not only enhances the understanding of patient responses to treatment but also paves the way for more effective therapeutic strategies.